Obesity Market Gains Weight But Better Drugs Still Needed
Executive Summary
The US obesity market is expected to double in size over the next decade with Novo Nordisk’s Saxenda driving the growth – but real progress for the pharmaceutical sector will only come when obesity drugs offer better outcomes than non-pharma methods.